Nature de la demande
Radiation
Arrêt du remboursement suite à un arrêt de commercialisation.
Avis favorable à l’arrêt du remboursement de la spécialité IMBRUVICA (ibrutinib) 140 mg, gélule dans les indications de l’AMM.
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
y6Pw4fKPS6MrrM30
